• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

3.320 -0.190 (-5.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AC Immune SA - Common Stock

< Previous 1 2 Next >
News headline image
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
December 11, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
November 11, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 04, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
October 28, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
October 24, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
September 25, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
September 04, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 05, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
April 30, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
April 02, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
March 25, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
March 13, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Participate in Upcoming Investor Conferences
March 04, 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
December 10, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
November 14, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
November 13, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 05, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 17, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
July 31, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
May 28, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From AC Immune SA
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap